-+ 0.00%
-+ 0.00%
-+ 0.00%

Prothena Q1 FY26 swings to net profit of $32.7 million; revenue more than doubled to $51.1 million

PUBT·05/07/2026 20:28:47
Listen to the news
Prothena Q1 FY26 swings to net profit of $32.7 million; revenue more than doubled to $51.1 million
  • Prothena posted 1Q 2026 net income of USD 32.7 million, swinging from a net loss of USD 60.2 million a year earlier; basic EPS was USD 0.61.
  • Revenue rose to USD 51.1 million from USD 2.8 million, driven mainly by a USD 50 million Novo Nordisk milestone tied to coramitug’s ongoing Phase 3 trial.
  • R&D expense fell to USD 12.6 million from USD 50.8 million; G&A expense declined to USD 12.7 million from USD 17.6 million.
  • Cash, cash equivalents and restricted cash totaled USD 330.3 million at March 31, with no debt; 2026 net cash used in operating and investing activities forecast at USD 18 million to USD 23 million.
  • Roche highlighted longer-term and exploratory analyses for prasinezumab in Parkinson’s disease, while Novo Nordisk secured FDA Fast Track for coramitug in ATTR-CM; Bristol Myers Squibb decision on advancing PRX019 expected by year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260507030808) on May 07, 2026, and is solely responsible for the information contained therein.